Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).

PubWeight™: 1.08‹?› | Rank: Top 10%

🔗 View Article (PMID 17525087)

Published in Ann Oncol on May 24, 2007

Authors

F De Vita1, F Giuliani, M Orditura, E Maiello, G Galizia, N Di Martino, F Montemurro, G Cartenì, L Manzione, S Romito, V Gebbia, F Ciardiello, G Catalano, G Colucci, Gruppo Oncologico Italia Meridionale

Author Affiliations

1: Division of Medical Oncology, Second University, Napoli, Italy. fernandodevita@yahoo.it

Articles citing this

Treatment of gastric cancer. World J Gastroenterol (2014) 1.93

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90

Barrett's adenocarcinoma of the esophagus: better outcomes through new methods of diagnosis and treatment. Dtsch Arztebl Int (2011) 1.72

Treatment of resectable gastric cancer. Therap Adv Gastroenterol (2012) 0.99

Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol (2008) 0.97

Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer (2012) 0.95

Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol (2015) 0.92

Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. J Cancer Res Clin Oncol (2008) 0.84

Chemotherapy for patients with gastric cancer after complete resection: a network meta-analysis. World J Gastroenterol (2014) 0.84

Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol (2014) 0.82

Surgery and adjuvant chemotherapy. Int J Clin Oncol (2008) 0.78

What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol (2014) 0.76

Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients. Cancer Res Treat (2014) 0.76

Adjuvant Chemotherapy for Advanced Gastric Cancer in Elderly and Non-elderly Patients: Meta-Analysis of Randomized Controlled Trials. Cancer Res Treat (2016) 0.75

Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience. Curr Oncol (2014) 0.75

Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. Oncol Lett (2014) 0.75

Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer. BMC Cancer (2016) 0.75

Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol (2016) 0.75

Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer. Cancer Med (2016) 0.75

Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. Exp Ther Med (2010) 0.75

Articles by these authors

Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32

Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol (2007) 3.26

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology (2001) 2.53

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007) 2.50

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 2.14

Effect of a single, oral, high-dose vitamin D supplementation on endothelial function in patients with peripheral arterial disease: a randomised controlled pilot study. Eur J Vasc Endovasc Surg (2012) 2.12

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol (2007) 2.11

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol (2000) 2.07

Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03

Use of octogenarian donors for liver transplantation: a survival analysis. Am J Transplant (2014) 2.00

The influence of a prolonged sitting position on the biochemical markers of coagulation activation in healthy subjects: evidence of reduced thrombin generation. J Thromb Haemost (2003) 1.96

Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol (1997) 1.94

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol (2000) 1.69

Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest (2005) 1.68

Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol (2009) 1.67

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer (2008) 1.62

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61

Radiofrequency thermal ablation of 69 lung neoplasms. J Chemother (2004) 1.58

Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res (1998) 1.54

Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol (2005) 1.54

Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol (2000) 1.54

Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer (1998) 1.50

Genes from mycoparasitic fungi as a source for improving plant resistance to fungal pathogens. Proc Natl Acad Sci U S A (1998) 1.50

Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical management. Jpn J Clin Oncol (1999) 1.48

Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol (1998) 1.47

A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast (2010) 1.47

Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia (2007) 1.42

Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nat Biotechnol (2001) 1.41

Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA. J Thromb Haemost (2009) 1.41

Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst (1997) 1.41

Standard vs. point-of-care measurement of fibrinogen: potential impact on clinical decisions. Minerva Anestesiol (2012) 1.40

Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res (2000) 1.40

Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods (1998) 1.36

Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol (2006) 1.33

Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J (2010) 1.33

Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest (2000) 1.32

Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol (2001) 1.32

Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs (1998) 1.31

Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology (1999) 1.31

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol (2009) 1.30

Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J Clin Microbiol (2006) 1.29

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol (2012) 1.28

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol (2007) 1.28

Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer (1995) 1.27

Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells. Mol Cell Biol (1990) 1.26

Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets (2010) 1.25

Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc Natl Acad Sci U S A (1994) 1.25

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol (2005) 1.24

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol (2009) 1.24

Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol (1994) 1.23

Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol (2005) 1.21

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer (2004) 1.20

Well differentiated "lipoma-like" liposarcoma of the sigmoid mesocolon and multiple lipomatosis of the rectosigmoid colon. Report of a case. Hepatogastroenterology (1999) 1.19

Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol (1995) 1.18

Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol (2001) 1.17

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol (2006) 1.17

Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology (2000) 1.17

Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res (1992) 1.17

The role of Aurora-A inhibitors in cancer therapy. Ann Oncol (2007) 1.16

Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets (2012) 1.15

A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol (2000) 1.13

Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res (1999) 1.12

Transforming growth factor-alpha: an oncodevelopmental growth factor. Cancer Cells (1990) 1.12

Stapled transanal rectal resection to treat obstructed defecation caused by rectal intussusception and rectocele. Int J Colorectal Dis (2006) 1.12

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood (2000) 1.11

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer (2006) 1.09

Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer (1994) 1.09

Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol (2001) 1.09

Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A (1987) 1.08

Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem (1997) 1.08

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer (1993) 1.08

Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells. Proc Natl Acad Sci U S A (1994) 1.07

Infection with a TGF-alpha retroviral vector transforms normal mouse mammary epithelial cells but not normal rat fibroblasts. Oncogene (1989) 1.06

In situ characterization by monoclonal antibodies of the mononuclear cell infiltrate in chronic active hepatitis. Gastroenterology (1983) 1.06

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol (2003) 1.06

Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev (2000) 1.05

Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer Treat Rev (2010) 1.05

Dasatinib: a new step in molecular target therapy. Ann Oncol (2007) 1.04

Tandem action of exercise training and food restriction completely preserves ischemic preconditioning in the aging heart. Exp Gerontol (2005) 1.04

Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev (2010) 1.02